BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
Key PointsBioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026.
Aggregator
11 tea kettles that might actually make you a ‘tea person’ this fall
I rounded up the best tea kettles, including electric and stovetop options, from brands like Smeg, Fellow and Cuisinart, after talking to tea experts.
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
Key PointsBioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026.
Tennis player Terence Atmane fires racket toward crowd and nearly hits spectators in epic tantrum
Terence Atmane spiked his racket, launched a ball over the grandstand and hurled his racket toward fans at the Shanghai Masters qualifying round in an epic tantrum.
Tennis player Terence Atmane fires racket toward crowd and nearly hits spectators in epic tantrum
Terence Atmane spiked his racket, launched a ball over the grandstand and hurled his racket toward fans at the Shanghai Masters qualifying round in an epic tantrum.
A Job Seeker Answered Every Interview Question With Gibberish. The AI Recruiter Became Hostile
A viral TikTok test pushed an automated job interviewer off script, raising questions about whether these systems can reliably judge human candidates.
SportsLine Newsletter Thursday, October 8, 2026
Today's best bets + Parlay of the Day + Missouri St.-Western Kentucky + Bucs-Cowboys TNF
NBA, FIBA say Europe push to continue without EuroLeague
The NBA and FIBA say they are undeterred in moving forward with the NBA Europe plan after EuroLeague's team owners rejected a merger offer this week.
Strength Seen in Viant (DSP): Can Its 7.1% Jump Turn into More Strength?
Viant (DSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Trump Accounts top 70 million as new stock-donation rules open door to 'mega donors,' official says
The Trump administration said new changes to Trump Accounts could pave the way for several multimillion-dollar donations.
F.B.I. Charges American in Plot Behind Canada’s Tumbler Ridge School Shooting
The U.S. police say a 30-year-old offered the killer advice and cash for supplies at least six months before the rampage in British Columbia that left eight dead.
Second suspected plague death reported
Experts demand transparency from Russia following reports of a second suspected plague death.
Senate Democrats Demand Apology From GOP Over Jack Smith Hearing
Senate Judiciary Committee Democrats have requested that panel chair, Sen. Chuck Grassley (R-Iowa), apologize to ex-special counsel Jack Smith on behalf of his Republican colleagues following a contentious hearing in September.
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from Sell
Fintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.On October 7, 2026,
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from Sell
Fintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.On October 7, 2026,
Founders Spend Years Trying to Meet the Right People. This Exclusive Malibu Event Puts Them Face-to-Face in One Day.
At Founderland, a “Coachella for founders,” entrepreneurs trade the convention hall for a Malibu ranch with access to retailers and investors.
Goldman Sachs’ Likely Next CEO Doesn’t Look Like Wall Street. That Could Be His Edge
A Wells Fargo analyst says John Waldron comes across like an English Lit professor, but his 26-year track record and how Goldman handles the executives he leaves behind will define the transition.
NVIDIA Commits $1 Bln To Advance U.S. Science Over Five Years
(RTTNews) - NVIDIA Corp. (NVDA) has announced commitments valued at $1 billion over the next five years to strengthen U.S. scientific research and development in areas including quantum computing, healthcare and energy security.
NVIDIA Commits $1 Bln To Advance U.S. Science Over Five Years
(RTTNews) - NVIDIA Corp. (NVDA) has announced commitments valued at $1 billion over the next five years to strengthen U.S. scientific research and development in areas including quantum computing, healthcare and energy security.
NVIDIA Commits $1 Bln To Advance U.S. Science Over Five Years
(RTTNews) - NVIDIA Corp. (NVDA) has announced commitments valued at $1 billion over the next five years to strengthen U.S. scientific research and development in areas including quantum computing, healthcare and energy security.